Testosterone Therapy, Prostate Safety, and Other Safety Issues



Testosterone replacement therapy has dramatically improved the quality of life of many men with late-onset hypogonadism. However, one concern that many doctors and patients have regarding this therapy is prostate safety. The main concern is the possible association with prostate cancer and minor concern with benign prostatic hyperplasia (BPH). As part of the natural history of the prostate, both the incidence and prevalence of both BPH and prostate cancer increase with aging men. In the natural scheme of things, testosterone level decreases with age. We were taught at medical school that prostate cancer and BPH are androgen dependent, and many doctors have great trepidation in giving the highly effective testosterone replacement therapy as a result of this. However, the current body of evidence generally sees no harm to the prostate in giving testosterone replacement therapy. There is no conclusive evidence (Roddam et al. 2008; Carpenter et al. 2008) that testosterone therapy increases the risk of prostate cancer or BPH.


Prostate Cancer Obstructive Sleep Apnea Benign Prostatic Hyperplasia Lower Urinary Tract Symptom International Prostate Symptom Score 


  1. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173:533–6.PubMedCrossRefGoogle Scholar
  2. Bhasin S, Singh AB, Mac R, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003;24:299–311.PubMedGoogle Scholar
  3. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451–7.PubMedCrossRefGoogle Scholar
  4. Carpenter WR, Robinson WR, Godley PA. Getting over testosterone: postulating a fresh start for etiologic studies of prostate cancer. J Natl Cancer Inst. 2008;100:158–9.PubMedCrossRefGoogle Scholar
  5. Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 2005;65:2082–4.PubMedCrossRefGoogle Scholar
  6. Davilla H, Arison C, Hall M, Salup R, Lockhart J, Carrion R. Analysis of the PSA response after testosterone supplementation in patients who previously received management for their localized prostate cancer. J Urol. 2008;179(Suppl):428, abstract 1247.CrossRefGoogle Scholar
  7. Fowler JE, Whitmore Jr WF. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol. 1981;126:372–5.PubMedGoogle Scholar
  8. Gaylis FD, Lin DW, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ. Prostate cancer in men using testosterone supplementation. J Urol. 2005;174:534–8, discussion 538.PubMedCrossRefGoogle Scholar
  9. Gooren LJ, Behre HM, Saad F, Frank A, Schwerdt S. Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research. Aging Male. 2007;10:173–81.PubMedCrossRefGoogle Scholar
  10. Huggins C, Hodges CV. Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7.Google Scholar
  11. Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol. 2009;56:48–56.PubMedCrossRefGoogle Scholar
  12. Jackson JA, Waxman J, Spiekerman AM. Prostatic complications of testosterone replacement therapy. Arch Intern Med. 1989;149:2365–6.PubMedCrossRefGoogle Scholar
  13. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172:920–2.PubMedCrossRefGoogle Scholar
  14. Loughlin KR, Richie JP. Prostate cancer after exogenous testosterone treatment for impotence. J Urol. 1997;157:1845.PubMedCrossRefGoogle Scholar
  15. Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int. 2009;103:62–4.PubMedCrossRefGoogle Scholar
  16. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: result of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003;170:2348–51.PubMedCrossRefGoogle Scholar
  17. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482–92.PubMedCrossRefGoogle Scholar
  18. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170–83.PubMedCrossRefGoogle Scholar
  19. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109:536–41.PubMedCrossRefGoogle Scholar
  20. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA. 1996;93:11802–7.PubMedCrossRefGoogle Scholar
  21. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol. 2009;55:121–30.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Department of UrologyChangi General HospitalSingaporeSingapore
  2. 2.Andropause and Men’s Health Clinic, Changi General HospitalSingaporeSingapore

Personalised recommendations